Assay News and Research

RSS

New H1N1 Influenza detection test used to diagnose Australia's first swine flu victim

When the first cases of H1N1 Influenza (swine flu) were reported in Mexico in April, UQ researchers got to work developing a test to diagnose the virus.

4 Sep 2009

Oncotype DX multigene expression test for breast cancer patients

In an effort to provide breast cancer patients with prompt, critical information about treatment options for use at their first visit with the medical oncologist, a number of leading U.S. surgeons request Genomic Health's Oncotype DX molecular test at the time of surgery or biopsy.

4 Sep 2009

Two new antibodies for targeting HIV virus discovered

Researchers at and associated with the International AIDS Vaccine Initiative (IAVI), at The Scripps Research Institute, and at the biotechnology companies Theraclone Sciences and Monogram Biosciences have discovered two powerful new antibodies to HIV that reveal what may be an Achilles heel on the virus. They published their work in Science this week.

3 Sep 2009

Clinical research paper on 2D gel electrophoresis for identifying protein biomarkers

Transgenomic, Inc. and Power3 Medical Products, Inc. (OTC Bulletin Board: PWRM) today announced the advance on-line publication of a clinical research paper entitled "Abnormal Serum Concentrations of Proteins in Parkinson's Disease" in the scientific journal Biochemical and Biophysical Research Communications.

3 Sep 2009

Molecular pathology laboratories gear up for swift swine flu detection

Dr. Jan Nowak, President of the Association for Molecular Pathology presented public comments today at the Clinical Laboratory Improvement Advisory Committee meeting.

3 Sep 2009

D3 Ultra DFA Respiratory Virus Identification Kit can be used for detecting H1N1 virus

Diagnostic HYBRIDS announced that the US Food and Drug Administration has cleared an additional claim for the company's D3 Ultra DFA Respiratory Virus Identification Kit, which confirms that the assay can detect the 2009 influenza A (H1N1)v virus.

31 Aug 2009

Gen-Probe commences its PROGENSA PCA3 assay clinical trial

Gen-Probe Incorporated announced today that the Company has begun a clinical trial intended to secure U.S. regulatory approval of its PROGENSA(R) PCA3 assay, a new molecular test that may help determine the need for a repeat prostate biopsy.

28 Aug 2009

Gen-Probe commences clinical study to secure U.S. approval of the PROGENSA PCA3 assay

DiagnoCure Inc. (TSX: CUR) announced that Gen-Probe, Inc. (NASDAQ: GPRO), its partner for the development and commercialization of the PCA3 prostate cancer test, has confirmed today the beginning of a U.S. clinical study intended to secure U.S. regulatory approval of the PROGENSA(R) PCA3 assay, a new molecular test that may help determine the need for a repeat prostate biopsy.

28 Aug 2009

Scientists discover a new way for preventing liver metastases

Scientists in Switzerland have discovered a way to block the growth of human colon cancer cells, preventing the disease from reaching advanced stages and the development of liver metastases. The research, published today in EMBO Molecular Medicine, shows that blocking the so-called Hedgehog-GLI pathway can prevent the growth of tumours, metastatic lesions and cancer stem cells, the cells thought to lie at the root of cancer growth.

27 Aug 2009

Peptimmune's Phase Ib clinical trial of PI-2301 in multiple sclerosis patients complete

Peptimmune, Inc., a privately held biotechnology company, announced the completion of a clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PI-2301 in subjects with Secondary Progressive Multiple Sclerosis (SP-MS). PI-2301 is a novel peptide copolymer for the treatment of multiple sclerosis and other autoimmune diseases.

26 Aug 2009

Positive results obtained from phase 3 clinical trial of lurasidone for treating schizophrenia

Dainippon Sumitomo Pharma Co., Ltd., (DSP) announced today positive results from PEARL 2 - a phase 3 clinical trial of lurasidone for the treatment of patients with schizophrenia. In this trial, both lurasidone 40 and 120 mg/day were significantly more effective than placebo for the treatment of schizophrenia. Lurasidone was well-tolerated with an overall discontinuation rate that was similar to placebo.

26 Aug 2009

Cytrx’s study offers a better perception of arimoclomol's mechanism of action in induced animal stroke

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today announced that study results demonstrated that arimoclomol exhibited both statistically significant neuroprotective and neuroregenerative effects in brain cells of animals induced with stroke, offering important insights into this drug candidate’s mechanism of action.

25 Aug 2009

Thyretain TSI Reporter BioAssay test for detecting auto-antibodies attains the FDA clearance

Diagnostic HYBRIDS announces the FDA clearance, for marketing under the 510(k) pre-notification process, of the Thyretain TSI Reporter BioAssay. Thyretain is an in vitro diagnostic use test that specifically detects auto-antibodies called thyroid stimulating immunoglobulins (TSI) in patient serum.

25 Aug 2009

Neurogen stockholders to receive $11 million in Ligand Pharmaceuticals common stock as part of acquisition deal

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and Neurogen Corporation (NASDAQ:NRGN) announced today they have entered into a definitive merger agreement under which Ligand will acquire Neurogen. Under the transaction, Neurogen stockholders will receive an estimated $11 million in Ligand common stock and will be granted Contingent Value Rights (“CVRs”) under four CVR agreements.

25 Aug 2009

SQI Diagnostics continues discussions with the FDA to market it's SQiDworks Diagnostics Platform in the US

SQI Diagnostics Inc. (TSX-V: SQD), a medical systems automation company focused on evolving laboratory-based biomarker testing, today announced its financial and operational results for the third quarter ended June 30, 2009.

24 Aug 2009

New noninvasive technique to detect colorectal and gastric cancers found

A preliminary evaluation of methylation of two gene promoters in fecal DNA showed promise as a noninvasive method to detect colorectal and gastric cancers, according to a new study published online August 21 in the Journal of the National Cancer Institute.

24 Aug 2009

Genway Clinical Laboratory offers ELISA-based test that detects tumor markers in blood serum

GenWay Clinical Laboratory, a US-based diagnostic company with CLIA certification, has validated a general tumor marker test in their laboratory and now offers this testing service. This is an ELISA-based assay which simply requires a small blood sample from the patient in order to quantify the amount of the tumor marker in their serum.

24 Aug 2009

Southern Research's Birmingham campus to have a Comprehensive Chemical Biology Center

Southern Research Institute today announced that it has been selected as one of 11 organizations to help establish the National Cancer Institute's (NCI) Chemical Biology Consortium (CBC)--a program meant to coordinate and accelerate the discovery and development of new therapeutic agents to treat cancer patients. Southern Research will establish one of NCI's five Comprehensive Chemical Biology Centers at its Birmingham campus.

21 Aug 2009

Chemical components of elderberry, cinnamon and green tea extracts block HIV viruses from infecting cells

The development of new antiviral drugs has had a tremendous impact on the quality of life and life expectancy of HIV-positive and AIDS patients, as the drugs effectively disrupt the replication cycle of the HIV virus. Yet the regular use of those drugs - such as zidovudine (also known as azidothymidine or AZT), protease inhibitors, and highly active antiretroviral therapy (HAART) involving multidrug therapies - has led to resistant HIV strains.

20 Aug 2009

DNA evidence found at crime scenes can easily be falsified

Nucleix, Ltd., an emerging life science company specializing in forensic DNA analysis, announced that company researchers have proven DNA evidence found at crime scenes can easily be falsified using basic equipment, know-how and access to DNA or a DNA database.

18 Aug 2009

Assay News and Research

New H1N1 Influenza detection test used to diagnose Australia's first swine flu victim

Oncotype DX multigene expression test for breast cancer patients

Two new antibodies for targeting HIV virus discovered

Clinical research paper on 2D gel electrophoresis for identifying protein biomarkers

Molecular pathology laboratories gear up for swift swine flu detection

D3 Ultra DFA Respiratory Virus Identification Kit can be used for detecting H1N1 virus

Gen-Probe commences its PROGENSA PCA3 assay clinical trial

Gen-Probe commences clinical study to secure U.S. approval of the PROGENSA PCA3 assay

Scientists discover a new way for preventing liver metastases

Peptimmune's Phase Ib clinical trial of PI-2301 in multiple sclerosis patients complete

Positive results obtained from phase 3 clinical trial of lurasidone for treating schizophrenia

Cytrx’s study offers a better perception of arimoclomol's mechanism of action in induced animal stroke

Thyretain TSI Reporter BioAssay test for detecting auto-antibodies attains the FDA clearance

Neurogen stockholders to receive $11 million in Ligand Pharmaceuticals common stock as part of acquisition deal

SQI Diagnostics continues discussions with the FDA to market it's SQiDworks Diagnostics Platform in the US

New noninvasive technique to detect colorectal and gastric cancers found

Genway Clinical Laboratory offers ELISA-based test that detects tumor markers in blood serum

Southern Research's Birmingham campus to have a Comprehensive Chemical Biology Center

Chemical components of elderberry, cinnamon and green tea extracts block HIV viruses from infecting cells

DNA evidence found at crime scenes can easily be falsified

Hasret Altan-Martin

Speeding Up Sample Preparation to Accelerate Analytical Chemistry

Ask the Expert: 7 Questions about Colorectal Cancer & Non-invasive Fecal DNA Testing

Latest News

Drug Discovery eBook